Despite the advances in the development of MEK inhibitors for cancer treatment, whether these drugs are useful for the treatment of iCCA, especially those with K-Ras-activating mutations, has been assessed only marginally, both in vitro and in vivo. This evidence concerns the gene MAP2K7 and infantile convulsions and choreoathetosis.